Days af­ter seal­ing Sanofi pact, Kymera beats a path to the Nas­daq with $100M IPO pitch

Back in March, when Kymera Ther­a­peu­tics closed $102 mil­lion in Se­ries C fund­ing led by Biotech­nol­o­gy Val­ue Fund and Red­mile Group, CEO Nel­lo Main­olfi …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.